Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXLHIO)

Drug Name

V158411 Drug Info

Synonyms

1174664-88-0; 1-Benzyl-N-(5-{5-[3-(Dimethylamino)-2,2-Dimethylpropoxy]-1h-Indol-2-Yl}-6-Oxo-1,6-Dihydropyridin-3-Yl)-1h-Pyrazole-4-Carboxamide; VER-00158411; 1-Benzyl-N-(5-(5-(3-(dimethylamino)-2,2-dimethylpropoxy)-1H-indol-2-yl)-6-oxo-1,6-dihydropyridin-3-yl)-1H-pyrazole-4-carboxamide; VER-158411; SCHEMBL950079; BCP25319; HY-18942; CS-0014655; Q27455647; V 158411; V-158411; VER00158411; VER 00158411; VER-00158411; 1-benzyl-N-[5-[5-[3-(dimethylamino)-2,2-dimethylpropoxy]-1H-indol-2-yl]-6-oxo-1H-pyridin-3-yl]pyrazole-4-carboxamide; 5CV

Indication

Disease Entry	ICD 11	Status	REF
Triple negative breast cancer	2C60-2C65	Investigative	[1]

Cross-matching ID

PubChem CID: 44198296
TTD Drug ID: DMXLHIO

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Checkpoint kinase-1 (CHK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LY2603618	DMCXRZF	Pancreatic cancer	2C10	Phase 2	[3]
UCN-01	DMUNJZB	Non-small-cell lung cancer	2C25.Y	Phase 2	[4]
SCH-900776	DM67EMK	Solid tumour/cancer	2A00-2F9Z	Phase 2	[5]
LY2606368	DM4XMF7	Ovarian cancer	2C73	Phase 2	[6]
LY2880070	DMADEHZ	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[7]
RG7741	DMK6P9J	Lymphoma	2A80-2A86	Phase 1	[8]
GDC-0425	DMDZ26X	Lymphoma	2A80-2A86	Phase 1	[9]
AZD7762	DM1FW0C	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
MK-8776	DMAS1RB	Hodgkin lymphoma	2B30	Phase 1	[11]
Diamidothiazole derivative 1	DM02V5Q	N. A.	N. A.	Patented	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Checkpoint kinase-1 (CHK1)	TTTU902	CHK1_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. BMC Cancer. 2014 Aug 7;14:570.
2	Cell Density Affects the Detection of Chk1 Target Engagement by the Selective Inhibitor V158411. SLAS Discov. 2018 Feb;23(2):144-153.
3	Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014 Apr;32(2):213-26.
4	Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening app... J Mol Graph Model. 2009 Sep;28(2):113-30.
5	Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602.
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer. Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 3581-3581.
8	National Cancer Institute Drug Dictionary (drug id 730054).
9	Quantitative assessment of BCL-2:BIM complexes as a pharmacodynamic marker for venetoclax (ABT-199).
10	Clinical pipeline report, company report or official report of AstraZeneca (2009).
11	Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. Int J Mol Sci. 2019 Aug 22;20(17):4095.
12	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.